Q-omics provides the consensus-scored MIR5692A1 profile across patient tissues and cancer cell-line models. MIR5692A1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MIR5692A1 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MIR5692A1 RNA expression shows 12,968 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight LIHC, KIRC, and SARC as cancer lineages where MIR5692A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5692A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5692A1 survival associations across molecular data types. MIR5692A1 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5692A1 RNA expression–survival associations across cancer types. High MIR5692A1 expression shows unfavorable associations in LIHC, LUSC, READ, KICH and UVM, but favorable associations in LAML. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MIR5692A1 RNA expression.
This table summarizes MIR5692A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5692A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5692A1 shows higher tumor expression in KIRC, ESCA and STAD. The KIRC box plot shows higher MIR5692A1 RNA expression in tumor versus normal tissue (log2 FC = +0.211, t-test p = .020).
This table shows molecular features associated with MIR5692A1 in patient tissues and cancer cell lines. In patient samples, MIR5692A1 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
